Pelabresib Anhydrous Crystalline Form B Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of stable crystalline forms of Pelabresib, a potent small molecule inhibitor of BET proteins, is crucial for enhancing its therapeutic efficacy and stability, particularly for conditions like myelofibrosis where it is being investigated in Phase 3 clinical trials.
Innovation Solution
The provision of an anhydrous crystalline Form B of Pelabresib, characterized by specific X-ray powder diffraction peaks, which is stable and non-hygroscopic, as evidenced by Differential Scanning Calorimetry and Dynamic Vapor Sorption analyses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the monohydrate form of Pelabresib is used for clinical trials, then the therapeutic potential can be realized, but the stability and hygroscopicity issues limit its performance
Solution Approach 1:
The patent applies parameter changes by transforming the crystalline form of Pelabresib from monohydrate to anhydrous forms. This fundamental parameter change in the chemical composition (removing water of crystallization) directly addresses the hygroscopicity issue while maintaining therapeutic efficacy, as demonstrated by the development of Forms I, II, and III with different anhydrous structures that exhibit improved stability profiles
Solution Approach 2:
The patent utilizes phase transitions by converting Pelabresib from its monohydrate crystalline phase to anhydrous crystalline phases through controlled heating and drying processes. This phase transition eliminates the water molecules from the crystal lattice, thereby reducing hygroscopicity while preserving the therapeutic properties of the compound
2Reliability
If stable crystalline forms are developed, then therapeutic efficacy is enhanced, but the complexity of characterizing and manufacturing multiple forms increases
Solution Approach 1:
The patent applies segmentation by dividing the complex problem of Pelabresib stability into distinct crystalline forms (Forms I, II, and III), each with specific characteristic properties. This segmentation allows for systematic characterization of each form's stability, solubility, and manufacturing properties, making the overall development process more manageable despite the multiplicity of forms
Solution Approach 2:
The patent systematically varies crystallization parameters (solvent type, temperature, pH, concentration) to generate different anhydrous crystalline forms. This parameter optimization approach allows for the identification of forms with desirable properties while establishing standardized manufacturing protocols that reduce complexity through methodical control of processing conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anhydrous crystalline Form B of Pelabresib demonstrates improved stability and reduced hygroscopicity, potentially leading to enhanced bioavailability and therapeutic effectiveness in treating conditions associated with BET protein inhibition, such as myelofibrosis.
Implementation Method 1
anhydrous crystalline Form B is characterized by X-ray powder diffraction peaks
Implementation Method 2
X-ray powder diffraction peaks at 2theta angles
Implementation Method 3
Differential Scanning Calorimetry (DSC) thermogram
Implementation Method 4
thermal gravimetric analysis (TGA) overlay
Implementation Method 5
the dynamic vapor sorption (DVS) profile for anhydrous crystalline Form B of Pelabresib
Data Source
AI summary
Provided is an anhydrous crystalline form of Pelabresib as well as its use for treating conditions associated with BET proteins.